Peptidos nootropicos: la investigacion detras de los compuestos de mejora cognitiva

Introduction: The Emerging Landscape of Nootropic Peptides

Nootropic peptides represent a rapidly evolving area of neuroscience research, occupying the intersection of neuropeptide biology, cognitive pharmacology, and regenerative medicine. Unlike classical nootropic compounds — small-molecule racetams, cholinergic agents, or stimulants — peptide-based nootropics interact with the brain through highly specific receptor-mediated pathways, often engaging neurotrophic signaling cascades that influence not only acute cognitive performance but also long-term neuronal health and plasticity.

The appeal of peptide nootropics in research settings lies in their biological specificity. Peptides are short chains of amino acids that mimic or modulate endogenous signaling molecules, meaning they can engage natural physiological pathways with a degree of precision that many synthetic small molecules cannot easily achieve. This specificity, however, comes with practical challenges — peptides are typically degraded rapidly by endogenous peptidases, have limited oral bioavailability, and often require parenteral or intranasal administration in experimental protocols.

This article provides a thorough review of seven nootropic peptides that have generated significant research interest: Selank, Semax, Dihexa (PNB-0408), P21 (P021), PE-22-28, Pinealon, and Cortagen. For each compound, we examine the proposed mechanism of action, the quality and stage of available evidence, and the broader context within nootropic peptide research. This review is intended for educational purposes only and does not constitute medical advice.

Selank: A Synthetic Tuftsin Analog with Anxiolytic and Nootropic Properties

Origins and Structure

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a structural analog of the naturally occurring immunomodulatory peptide tuftsin, which itself is a fragment (residues 289–292) of the heavy chain of immunoglobulin G (IgG). Selank was created by attaching a stabilizing Pro-Gly-Pro sequence to the C-terminus of the tuftsin tetrapeptide Thr-Lys-Pro-Arg, which significantly increases the molecule's resistance to enzymatic degradation and extends its biological half-life.

The design rationale behind Selank was to retain and amplify the neuroactive properties observed in tuftsin research while creating a compound stable enough for practical experimental and clinical use. Tuftsin had been previously noted in research literature for effects extending beyond its classical immunostimulatory role, including potential influences on brain function.

Mechanism of Action

Selank's proposed mechanism of action is multifaceted, involving several neurotransmitter systems and neurotrophic pathways:

• GABAergic Modulation: Research suggests that Selank may enhance the activity of the gamma-aminobutyric acid (GABA) system, the brain's primary inhibitory neurotransmitter network. Studies in animal models have indicated that Selank may allosterically modulate GABA-A receptors, potentially enhancing inhibitory neurotransmission without the direct agonist activity associated with benzodiazepines. This proposed mechanism is central to its investigated anxiolytic properties.
• Serotonin and Dopamine Metabolism: Selank has been studied for its effects on monoamine neurotransmitter metabolism. Research in rodent models has reported changes in the metabolism of serotonin (5-HT) and dopamine in several brain regions, including the hypothalamus, hippocampus, and frontal cortex. These effects are proposed to contribute to both its anxiolytic and potential nootropic properties.
• Brain-Derived Neurotrophic Factor (BDNF): Some research has indicated that Selank administration may influence BDNF expression. BDNF is a key neurotrophin involved in synaptic plasticity, memory consolidation, and neuronal survival — processes directly relevant to cognitive function.
• Enkephalin System: Selank has been reported in some studies to influence the enkephalinase enzyme system, potentially modulating the degradation of endogenous enkephalins. This pathway could relate to both its anxiolytic and analgesic research profiles.
• Gene Expression Changes: Transcriptomic studies have reported that Selank administration in animal models can alter the expression of a substantial number of genes, including those involved in GABAergic neurotransmission, inflammatory signaling, and neurotrophic pathways. These broad transcriptional effects suggest that Selank's mechanism extends well beyond any single receptor interaction.

Research Profile and Regulatory Status

Selank has received regulatory approval in Russia as an anxiolytic medication, where it is available as an intranasal spray formulation. The Russian approval was based on clinical studies conducted primarily within Russian research institutions. In those studies, Selank demonstrated anxiolytic effects in patients with generalized anxiety, with researchers noting the absence of sedation, dependence potential, or withdrawal effects commonly associated with benzodiazepine anxiolytics.

Preclinical research in animal models has explored Selank's effects on learning and memory tasks, reporting improvements in various cognitive paradigms including passive avoidance, spatial navigation, and conditioned response tasks. However, the majority of published human clinical data comes from Russian-language literature, and large-scale randomized controlled trials meeting Western regulatory standards remain limited.

Selank is not approved by the FDA or EMA and remains an investigational compound outside of Russia.

Semax: A Synthetic ACTH Fragment with Neuroprotective Research

Origins and Structure

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic peptide analog of the adrenocorticotropic hormone (ACTH) fragment 4-10, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside Selank. Like Selank, Semax incorporates a C-terminal Pro-Gly-Pro sequence to enhance metabolic stability. However, it is crucial to note that despite being derived from an ACTH fragment, Semax does not exhibit the hormonal (steroidogenic) activity of ACTH — it does not stimulate cortisol release from the adrenal glands. The melanocortin-related signaling it engages is specifically the neuromodulatory arm of melanocortin activity in the central nervous system.

Mechanism of Action

Semax has been one of the more extensively studied nootropic peptides in terms of mechanism, with research spanning several decades:

• BDNF and NGF Upregulation: A central focus of Semax research has been its reported ability to stimulate the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Multiple animal studies have reported dose-dependent increases in BDNF mRNA and protein levels in several brain regions following Semax administration. BDNF plays a critical role in long-term potentiation, the cellular mechanism believed to underlie learning and memory.
• Melanocortin Receptor Activity: As an ACTH analog, Semax interacts with melanocortin receptors, particularly MC3 and MC4 subtypes expressed in the brain. Melanocortin signaling in the central nervous system has been implicated in attention, learning, memory consolidation, and neuroprotection. This pathway distinguishes Semax mechanistically from most other nootropic peptides.
• Neuroprotection: Significant research interest has focused on Semax's potential neuroprotective effects. Animal models of ischemic stroke have shown that Semax administration may reduce infarct volume and improve functional outcomes. The proposed neuroprotective mechanisms include antioxidant activity, anti-inflammatory effects, modulation of apoptotic pathways, and enhancement of neurotrophic support to vulnerable neurons.
• Dopaminergic and Serotonergic Effects: Semax has been studied for its effects on monoamine neurotransmitter systems. Research has reported increases in dopamine and serotonin turnover in specific brain regions, which may contribute to its proposed effects on attention, motivation, and mood.
• Gene Expression and Transcriptomic Effects: Large-scale gene expression studies have demonstrated that Semax can modulate the expression of hundreds of genes in the brain, including those involved in neurotrophin signaling, immune response, vascular function, and cellular stress responses. This broad transcriptomic footprint suggests pleiotropic neuroprotective and neuromodulatory effects.

Research Profile and Regulatory Status

Semax has been approved in Russia for the treatment of conditions including ischemic stroke recovery, cognitive disorders, peptic ulcers (via a stress-reduction mechanism), and as a general nootropic agent. It is administered intranasally in approved Russian formulations, typically as a 0.1% or 1% solution.

The Russian clinical research on Semax spans several decades and includes studies in stroke patients, individuals with cognitive impairment, and healthy volunteers. Researchers have reported improvements in attention, memory, and cognitive processing speed, as well as neuroprotective effects in stroke recovery. The safety profile in these studies has generally been favorable, with minimal reported adverse effects.

As with Selank, Semax is not approved by the FDA or EMA, and the majority of clinical evidence comes from Russian-language publications. Western regulatory-standard randomized controlled trials remain limited.

Dihexa (PNB-0408): An Angiotensin IV Analog with Potent Neurotrophic Activity

Origins and Structure

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide), also designated PNB-0408, is a synthetic peptide analog developed by researchers at Washington State University, most notably in the laboratory of Dr. Joseph Harding and Dr. John Wright. It was designed as a stable, orally active analog of angiotensin IV (Ang IV), the hexapeptide fragment of angiotensin II that binds to the AT4 receptor (now identified as insulin-regulated aminopeptidase, or IRAP).

What makes Dihexa remarkable in research literature is the extraordinary potency reported in preclinical studies. Researchers described it as being up to 10 million times more potent than BDNF in promoting neuronal connectivity in certain in vitro assays — a claim that, while striking, requires careful contextual interpretation.

Mechanism of Action

Dihexa's proposed mechanism centers on a novel neurotrophic signaling pathway:

• HGF/c-Met Pathway: The primary proposed mechanism for Dihexa's neurotrophic activity involves the hepatocyte growth factor (HGF) and its receptor, c-Met. Research from the Harding laboratory has shown that Dihexa can facilitate HGF/c-Met signaling by acting as a facilitator of HGF dimerization, which is required for full c-Met receptor activation. The HGF/c-Met axis is known to promote neuronal survival, neurite outgrowth, and synaptogenesis during development, and to participate in synaptic plasticity in the adult brain.
• Synaptogenesis: In vitro studies demonstrated that Dihexa could promote the formation of new synaptic connections between neurons at remarkably low concentrations. This synaptogenic activity is proposed to underlie its cognitive-enhancing effects observed in animal behavioral studies.
• IRAP Interaction: As an angiotensin IV analog, Dihexa also interacts with IRAP. The physiological significance of this interaction in the brain remains an area of active investigation, but IRAP inhibition has been independently associated with memory enhancement in animal models, possibly through modulation of neuropeptide availability at synapses.

Research Profile and Evidence Quality

The evidence for Dihexa comes almost exclusively from preclinical research. Animal studies in aged rats and in scopolamine-induced cognitive impairment models have reported significant improvements in spatial learning and memory tasks. The compound demonstrated efficacy when administered both centrally and peripherally, including via oral gavage, suggesting potential oral bioavailability — a significant practical advantage for peptide compounds.

However, several important caveats must be noted regarding Dihexa research:

• The published research comes primarily from a single laboratory group, and independent replication by other research groups remains limited.
• The "10 million times more potent than BDNF" claim refers to specific in vitro assay conditions and should not be extrapolated to in vivo potency comparisons.
• No human clinical trials have been published as of the time of this review.
• The HGF/c-Met pathway is also implicated in certain oncogenic processes, and the long-term safety implications of potent HGF/c-Met activation have not been thoroughly evaluated.
• Dihexa is not approved by any regulatory agency and remains an early-stage research compound.

A company called Athira Pharma (formerly M3 Biotechnology) was developing related compounds based on similar HGF/c-Met modulating technology, but the clinical program encountered setbacks, and the relationship between those clinical candidates and Dihexa itself is not straightforward.

P21 (P021): A CNTF-Derived Peptide Targeting Neurogenesis

Origins and Structure

P21, also referred to as P021, is a small synthetic peptide (Ac-DGGL-NH2) derived from the active region of ciliary neurotrophic factor (CNTF). It was developed by researchers at the New York State Institute for Basic Research in Developmental Disabilities, including Dr. Khalid Iqbal, a prominent Alzheimer's disease researcher. P21 was designed to capture the neurotrophic properties of CNTF in a smaller, more drugable molecular format that could potentially cross the blood-brain barrier.

Mechanism of Action

P21's proposed mechanism involves a dual pathway approach to promoting neuroplasticity:

• BDNF Pathway Enhancement: Research suggests that P21 can increase BDNF signaling, particularly in the hippocampus, a brain region critical for learning and memory. The increase in BDNF expression is proposed to support synaptic plasticity and the survival of newly generated neurons.
• Neurogenesis Stimulation: A key area of P21 research has been its reported ability to promote adult hippocampal neurogenesis — the generation of new neurons in the dentate gyrus of the hippocampus. Adult neurogenesis is believed to play important roles in pattern separation, spatial memory, and mood regulation. P21 has been reported to increase the proliferation and survival of neural progenitor cells in the hippocampus of both young and aged animal models.
• Anti-Tau and Anti-Amyloid Effects: In transgenic mouse models of Alzheimer's disease, P21 treatment has been associated with reduced tau hyperphosphorylation and decreased amyloid plaque burden. These effects are proposed to be secondary to the enhancement of neurotrophic support and may involve inhibition of glycogen synthase kinase 3-beta (GSK-3β), a kinase implicated in tau phosphorylation.
• Dendritic Complexity: Morphological studies have reported that P21 treatment increases dendritic branching and spine density in hippocampal neurons, structural changes associated with enhanced synaptic connectivity and cognitive function.

Research Profile and Evidence Quality

P21 has been studied in several animal models relevant to neurodegenerative disease and cognitive aging. Research in transgenic Alzheimer's disease mouse models (3xTg-AD) has shown improvements in learning and memory alongside the neurobiological changes described above. Studies in aged wild-type rats have reported similar cognitive benefits, suggesting that P21's effects are not limited to disease models but may also address age-related cognitive decline.

Notably, P21 has demonstrated efficacy when administered peripherally (subcutaneous injection or even oral administration in some studies), suggesting adequate bioavailability for systemic delivery. The compound has shown a favorable safety profile in animal studies, without the weight-loss side effects associated with full-length CNTF.

However, P21 remains in the preclinical stage. No human clinical trials have been published, and the translation of neurogenesis-promoting effects from rodent models to humans is a significant and unresolved question in neuroscience, as the extent and functional significance of adult human hippocampal neurogenesis remains debated.

PE-22-28: A Novel PACAP-Derived Nootropic Peptide

Origins and Structure

PE-22-28 is a synthetic peptide fragment derived from pituitary adenylate cyclase-activating polypeptide (PACAP), specifically corresponding to a modified segment of the PACAP sequence. PACAP is a 38-amino-acid neuropeptide with broad neurotrophic, neuromodulatory, and neuroprotective functions in the central nervous system. It exists in two biologically active forms — PACAP-38 and the truncated PACAP-27 — and acts through three receptors: PAC1 (PACAP-specific), VPAC1, and VPAC2 (shared with vasoactive intestinal peptide, VIP).

PE-22-28 was developed to capture specific cognitive-enhancing properties of PACAP signaling while reducing the peptide to a much smaller, more tractable molecular format.

Mechanism of Action

• PAC1 Receptor Signaling: PE-22-28 is proposed to act primarily through the PAC1 receptor, which is highly expressed in brain regions involved in learning and memory, including the hippocampus, cortex, and amygdala. PAC1 receptor activation stimulates adenylate cyclase and intracellular cyclic AMP (cAMP) production, engaging downstream signaling cascades including protein kinase A (PKA) and cAMP response element-binding protein (CREB). CREB phosphorylation is one of the most well-established molecular signatures of memory consolidation.
• Neurotrophic Support: Through PAC1-mediated signaling, PE-22-28 may promote the expression of neurotrophic factors and support neuronal survival and plasticity. PACAP signaling has been extensively linked to BDNF expression, anti-apoptotic signaling, and antioxidant defense mechanisms in neurons.
• Synaptic Plasticity: The cAMP/PKA/CREB pathway engaged by PAC1 receptor activation is central to long-term potentiation (LTP) in the hippocampus, making PE-22-28 mechanistically well-positioned as a potential cognitive enhancer from a theoretical standpoint.

Research Profile and Evidence Quality

PE-22-28 is among the newer nootropic peptides in research, and the available evidence base is accordingly limited. Published research comes from a small number of studies, primarily in rodent behavioral models. While the parent molecule PACAP has an extensive and robust research literature supporting its roles in cognition and neuroprotection, the specific pharmacological characterization of the PE-22-28 fragment is still in early stages.

Researchers interested in PE-22-28 should note that it represents an attempt to isolate and miniaturize a specific functional domain of a well-characterized neuropeptide. The broader PACAP literature provides theoretical support for the peptide's proposed mechanism, but direct evidence for PE-22-28 specifically remains preliminary. No clinical studies have been conducted.

Pinealon: A Tripeptide Bioregulator for Brain and Pineal Function

Origins and Structure

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator developed within the framework of the Russian bioregulatory peptide research program, principally associated with the work of Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. This program has developed a series of short peptides (typically 2–4 amino acids) proposed to act as gene regulators, capable of penetrating the cell nucleus and interacting directly with DNA to modulate gene expression in tissue-specific ways.

Mechanism of Action

The proposed mechanism for Pinealon differs fundamentally from the receptor-mediated mechanisms of peptides like Selank or Semax:

• Epigenetic Gene Regulation: According to the bioregulator peptide theory, Pinealon interacts with specific DNA sequences in the promoter regions of genes related to brain and pineal gland function, modulating their expression at the transcriptional level. This proposed mechanism of direct peptide-DNA interaction has been described in several publications from the Khavinson laboratory, though it remains outside the mainstream of Western peptide pharmacology.
• Pineal Gland Function: Pinealon is specifically proposed to support the function of the pineal gland, which produces melatonin and plays a critical role in circadian rhythm regulation. Research from the developing laboratory has reported that Pinealon can influence melatonin synthesis and pineal cell viability under stress conditions.
• Neuroprotection: Cell culture studies have examined Pinealon's effects on neurons exposed to various stressors, including oxidative stress and hypoxia. Some studies have reported protective effects, with reduced cell death markers and improved cell viability in Pinealon-treated cultures.
• Antioxidant Properties: Research has suggested that Pinealon may have antioxidant properties, potentially reducing reactive oxygen species and oxidative damage in neural tissues.

Research Profile and Evidence Quality

Pinealon is part of a broader family of bioregulator peptides that have been extensively studied within Russian scientific institutions. The published literature includes cell culture studies, animal experiments, and some human observational studies, primarily in elderly populations. Reported benefits include improvements in cognitive function, sleep quality, and markers of brain aging in elderly subjects.

However, several significant caveats apply to the Pinealon evidence base:

• The proposed mechanism of direct peptide-DNA interaction for such short peptides is not widely accepted in mainstream molecular pharmacology and requires further independent validation.
• Much of the published research comes from a single research network, and independent replication by international groups remains limited.
• The specificity of a tripeptide for particular DNA sequences is thermodynamically questionable, given the limited number of molecular contacts a three-amino-acid peptide can make with DNA.
• Human studies have generally been small and often lack rigorous blinding and randomization by Western clinical trial standards.

Pinealon is not approved by any major Western regulatory agency and should be considered an early-stage research compound.

Cortagen: A Bioregulator Peptide for Cortical Function

Origins and Structure

Cortagen (Ala-Glu-Asp-Pro) is another synthetic tetrapeptide bioregulator from the Khavinson research program, designed to target cerebral cortex function. Like Pinealon, it belongs to the class of short bioregulatory peptides proposed to influence gene expression in a tissue-specific manner.

Mechanism of Action

• Cortex-Specific Gene Regulation: Cortagen is proposed to interact with DNA sequences relevant to cortical neuron function, modulating the expression of genes involved in neuronal signaling, neurotrophic support, and neuroprotection. The tissue specificity — cortical neurons rather than pineal cells — is proposed to arise from the specific amino acid sequence of the peptide and its preferential interaction with particular DNA motifs.
• Neuroprotection: Cell culture studies have examined Cortagen's effects on cortical neurons under stress conditions, with some studies reporting reduced apoptosis and improved neuronal survival.
• Cognitive Function: Animal studies have investigated Cortagen's effects on learning and memory tasks, with some publications reporting improvements in aged or cognitively impaired animals.

Research Profile and Evidence Quality

Cortagen shares the same evidence profile strengths and limitations as Pinealon and other bioregulatory peptides from the Khavinson program. Published research includes in vitro, animal, and limited human observational data, primarily from Russian institutions. Some clinical studies in elderly populations have reported improvements in cognitive function and brain biomarkers, but the evidence has not been subjected to the level of scrutiny typically required for Western regulatory approval.

As with all bioregulator peptides, the proposed mechanism remains the subject of scientific debate, and independent international validation is needed before firm conclusions can be drawn about Cortagen's efficacy and mechanism of action.

Comparative Analysis: Mechanisms, Evidence Quality, and Research Stages

Mechanistic Diversity

One of the most striking aspects of the nootropic peptide landscape is the diversity of proposed mechanisms. These seven peptides represent at least four fundamentally different approaches to cognitive enhancement:

• Neurotransmitter Modulation: Selank (GABAergic, monoaminergic) operates primarily through classical neurotransmitter systems, similar in principle to traditional pharmacological approaches but with potentially greater selectivity.
• Neurotrophic Factor Enhancement: Semax (BDNF/NGF upregulation), Dihexa (HGF/c-Met facilitation), P21 (BDNF/neurogenesis), and PE-22-28 (cAMP/CREB pathway) all target neurotrophic signaling, though through different upstream mechanisms. This convergence on neurotrophic pathways reflects the growing consensus in neuroscience that synaptic plasticity and neuronal health are fundamental to cognitive function.
• Melanocortin Signaling: Semax's engagement of melanocortin receptors represents a unique mechanism among nootropic compounds, tapping into a neuropeptide system with broad modulatory effects on attention, motivation, and neural plasticity.
• Bioregulatory (Epigenetic): Pinealon and Cortagen propose a fundamentally different mechanism — direct gene regulation via peptide-DNA interaction — that, if validated, would represent a novel pharmacological paradigm.

Evidence Quality Hierarchy

The evidence quality across these peptides varies substantially. Arranged roughly from strongest to weakest evidence base:

1. Semax: The most extensive evidence base, including decades of preclinical research, multiple clinical studies (primarily Russian), regulatory approval in Russia for several indications, and a growing body of transcriptomic and mechanistic data. The evidence for neuroprotective effects in stroke models is particularly robust in preclinical settings.
2. Selank: Strong preclinical evidence, Russian regulatory approval as an anxiolytic, and some clinical data supporting anxiolytic and nootropic effects. The evidence base for cognitive effects specifically is less extensive than for Semax.
3. P21: A solid preclinical evidence base from a respected Alzheimer's disease research group, with consistent findings across multiple animal models. The mechanistic rationale is well-supported by the broader CNTF and neurogenesis literature.
4. Dihexa: Intriguing preclinical data with a novel mechanism, but limited to a single primary research group. The potency claims are notable but require independent replication and contextual interpretation. Safety concerns related to HGF/c-Met signaling warrant attention.
5. PE-22-28: A strong theoretical basis in PACAP biology but limited direct evidence for the specific fragment. The broader PACAP literature is supportive but cannot be directly extrapolated.
6. Pinealon and Cortagen: The bioregulator peptides have a substantial publication record from Russian institutions but face significant questions about the plausibility of their proposed mechanism. Independent international validation is particularly needed for these compounds.

Research Stage Summary

None of the seven peptides reviewed here have completed the full regulatory approval process in Western countries (FDA, EMA). Selank and Semax have achieved regulatory approval in Russia. Dihexa-related compounds have entered early clinical development through Athira Pharma, though the program has encountered challenges. P21, PE-22-28, Pinealon, and Cortagen remain in preclinical stages of development by Western standards.

Looking Ahead: The Future of Nootropic Peptide Research

Nootropic peptide research sits at a fascinating juncture. The mechanistic understanding of how peptides influence cognitive function has advanced considerably, particularly regarding neurotrophic factor signaling, synaptic plasticity, and neurogenesis. The diversity of approaches represented by the peptides reviewed here suggests that peptide-based cognitive enhancement could eventually address multiple aspects of brain health simultaneously.

However, significant translational challenges remain. The transition from promising preclinical findings to validated clinical outcomes has proven difficult for many neuroprotective and nootropic compounds across pharmacology. Practical challenges related to peptide stability, bioavailability, and blood-brain barrier penetration continue to drive research into novel delivery methods and stabilized peptide analogs.

The growing accessibility of advanced neuroimaging, biomarker technologies, and cognitive assessment tools may help accelerate clinical research by providing more sensitive endpoints for detecting cognitive effects in human studies. Additionally, as our understanding of the molecular basis of cognitive aging and neurodegeneration deepens, the rational design of peptide-based interventions targeting specific pathways will likely become increasingly sophisticated.

Researchers and those following this field should approach nootropic peptide claims with appropriate scientific caution, recognizing the distance between preclinical promise and proven clinical utility. The compounds reviewed here represent an active and evolving area of research that warrants continued scientific attention.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult qualified healthcare professionals regarding any health-related questions or decisions.